I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
Ann: SCENESSE Treatment in Europe-CUV.AX, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$11.76 |
Change
0.510(4.53%) |
Mkt cap ! $589.4M | |||
| Open | High | Low | Value | Volume |
| $11.25 | $11.81 | $11.14 | $1.328M | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $11.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.81 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |